High-dose gadoteridol in MR imaging of intracranial neoplasms

✍ Scribed by Val M. Runge; John E. Kirsch; Vickie J. Burke; Ann C. Price; Kevin L. Nelson; Greg S. Thomas; Bruce L. Dean; Charles Lee

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 964 KB
• Volume: 2
• Category: Article
• ISSN: 1053-1807
• DOI: 10.1002/jmri.1880020103

✦ Synopsis

Abstract

Twelve patients with a high suspicion of brain metastases by previous clinical or radiologic examinations were studied in a phase III investigation with magnetic resonance (MR) imaging at 1.5 T after a bolus intravenous injection of 0.1 mmol/kg gadoteridol followed at 30 minutes by a second bolus injection of 0.2 mmol/kg gadoteridol. All lesions were best demonstrated (showed greatest enhancement) at the 0.3‐mmol/kg (cumulative) dose, with image analysis confirming signal intensity enhancement in the majority of cases after the second gadoteridol injection. More lesions were detected with the 0.3‐mmol/kg dose than with the 0.1‐mmol/kg dose, and more lesions were detected with the 0.1‐mmol/kg dose than on precontrast images. In this limited clinical trial, high‐dose gadoteridol injection (0.3‐mmol/kg cumulative dose) provided improved lesion detection on MR images specifically in intracranial metastatic disease.